- O
Oncostellae
- Cristina Castro Fernández
Cristina Castro Fernández has a strong background in biomedical research. Cristina worked as a Clinical Project Manager at Oncostellae from February 2019 to the present. Prior to that, they were a Research Biologist at the Fundación Instituto de Investigación Sanitaria de Santiago de Compostela starting in June 2016. Before that, they held the same role at the Universidade de Santiago de Compostela from September 2013 to February 2016. In October 2012, they obtained their MSc in Biomedical Research from the Fundación Pública Gallega de Medicina Xenómica.
Cristina Castro Fernández completed their education history in the following chronological order:
1. From 2013 to 2019, they attended Universidad de Santiago de Compostela and obtained a Doctorado degree in Medicina molecular.
2. In 2017, they also briefly attended the University of Valencia and obtained an Experto Universitario en Genética Médica degree in the field of Biología humana.
3. From 2012 to 2013, Cristina Castro Fernández attended Universidad de Santiago de Compostela, but the specific degree and field of study during this period were not provided.
4. Before attending Universidad de Santiago de Compostela, they completed a Licenciatura en Biología degree with a focus on Molecular Biology at Universidad de León. The start and end years for this degree were not provided.
Org chart
This person is not in the org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
Oncostellae
Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company.
